Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants

Abstract

Main conclusion

The plant cell is able to produce the VP40 antigen from the Zaire ebolavirus , retaining the antigenicity and the ability to induce immune responses in BALB/c mice.

The recent Ebola outbreak evidenced the need for having vaccines approved for human use. Herein we report the expression of the VP40 antigen from the Ebola virus as an initial effort in the development of a plant-made vaccine that could offer the advantages of being cheap and scalable, which is proposed to overcome the rapid need for having vaccines to deal with future outbreaks. Tobacco plants were transformed by stable DNA integration into the nuclear genome using the CaMV35S promoter and a signal peptide to access the endoplasmic reticulum, reaching accumulation levels up to 2.6 µg g−1 FW leaf tissues. The antigenicity of the plant-made VP40 antigen was evidenced by Western blot and an initial immunogenicity assessment in test animals that revealed the induction of immune responses in BALB/c mice following three weekly oral or subcutaneous immunizations at very low doses (125 and 25 ng, respectively) without accessory adjuvants. Therefore, this plant-based vaccination prototype is proposed as an attractive platform for the production of vaccines in the fight against Ebola virus disease outbreaks.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Abbreviations

EVD:

Ebola virus disease

EBOV:

Ebola virus

GP:

Glycoprotein

VP:

Viral protein

References

  1. Becquart P, Mahlakõiv T, Nkoghe D, Leroy EM (2014) Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. PLoS One 6:e96360. doi:10.1371/journal.pone.0096360

  2. Benchabane M, Goulet C, Rivard D, Faye L, Gomord V, Michaud D (2008) Preventing unintended proteolysis in plant protein biofactories. Plant Biotechnol J 6:633–648

  3. Bociaga-Jasik M, Piatek A, Garlicki A (2014) Ebola virus disease—pathogenesis, clinical presentation and management. Folia Med Cracov 54:49–55

  4. Cangelosi GA, Best EA, Martinetti G, Nester EW (1991) Genetic analysis of Agrobacterium. Methods Enzymol 204:384–397

  5. Chia MY, Hsiao SH, Chan HT, Do YY, Huang PL, Chang HW, Tsai YC, Lin CM, Pang VF, Jeng CR (2011) Evaluation of the immunogenicity of a transgenic tobacco plant expressing the recombinant fusion protein of GP5 of porcine reproductive and respiratory syndrome virus and B subunit of Escherichia coli heat-labile enterotoxin in pigs. Vet Immunol Immunopathol 140:215–225

  6. Connell TD (2007) Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines 6:821–834

  7. De Martinis D, Rybicki EP, Fujiyama K, Franconi R, Benvenuto E (2016) Editorial: plant molecular farming: fast, scalable, cheap, sustainable. Front Plant Sci 7:1148

  8. Dellaporta SL, Wood J, Hicks JB (1983) A plant DNA minipreparation: version II. Plant Mol Biol Rep 1:19–21

  9. Feldmann H, Sanchez A, Geisbert TW (2006) Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 1409–1448

  10. Freed EO (2002) Viral late domains. J Virol 76:4679–4687

  11. Govea-Alonso DO, Cardineau GQ, Rosales-Mendoza S (2014) Principles of plant-based vaccines. In: Rosales-Mendoza S (ed) Genetically engineered plants as a source of vaccines against wide spread diseases—an integrated view. Springer Science + Business Media, New York, pp 1–14. ISBN 978-1-4939-0850-9

  12. Hernández M, Rosas G, Cervantes J, Fragoso G, Rosales-Mendoza S, Sciutto E (2014) Transgenic plants: a 5-year update on oral antipathogen vaccine development. Expert Rev Vaccines 12:1523–1536

  13. Horsch RB, Fry JE, Hoffmann NL, Eichholtz D, Rogers SG, Fraley RT (1985) A simple and general method for transferring genes into plants. Science 227:1229–1231

  14. Ingham DJ, Beer S, Money S, Hansen G (2001) Quantitative real-time PCR assay for determining transgene copy number in transformed plants. Biotechniques 31(132–134):136–140

  15. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y (2001) Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 75:5205–5214

  16. Jefferson RA (1987) Assaying chimeric genes in plants: the GUS gene fusion system. Plant Mol Biol Rep 5:387–405

  17. Kim SI, Veena JH, Gelvin SB (2007) Genome-wide analysis of Agrobacterium T-DNA integration sites in the Arabidopsis genome generated under non-selective conditions. Plant J 51:779–791

  18. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155:2083–2103

  19. Leroy EM, Epelboin A, MondongeV Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, Formenty P (2009) Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo. Vector Borne Zoonotic Dis 9:723–728

  20. Loos A, Steinkellner H (2014) Plant glyco-biotechnology on the way to synthetic biology. Front Plant Sci 5:523

  21. Lugade AA, Kalathil S, Heald JL, Thanavala Y (2010) Transgenic plant-based oral vaccines. Immunol Invest 39:468–482

  22. Marsh GA, Haining J, Robinson R, Foord A, Yamada M, Barr JA (2011) Ebola Reston virus Infection of pigs: clinical significance and transmission potential. J Infect Dis 204:S804–S809

  23. McCarthy M (2014) US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349:g5488

  24. Monreal-Escalante E, Govea-Alonso DO, Hernández M, Cervantes J, Salazar-González JA, Romero-Maldonado A, Rosas G, Garate T, Fragoso G, Sciutto E, Rosales-Mendoza S (2016) Towards the development of an oral vaccine against porcine cysticercosis: expression of the protective HP6/TSOL18 antigen in transgenic carrots cells. Planta 3:675–685

  25. Nawar HF, Arce S, Russell MW, Connell TD (2005) Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside binding activities. Infect Immun 73:1330–1342

  26. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y (2002) Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 76:4855–4865

  27. Noda T, Hagiwara K, Sagara H, Kawaoka Y (2010) Characterization of the Ebola virus nucleoprotein–RNA complex. J Gen Virol 91:1478–1483

  28. Phoolcharoen W, Bhoo SH, Lai H, Ma J, Arntzen CJ, Chen Q, Mason HS (2011) Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol J 9:807–816

  29. Pillet S, Aubin É, Trépanier S, Bussière D, Dargis M, Poulin JF, Yassine-Diab B, Ward BJ, Landry NA (2016) Plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. Clin Immunol 168:72–87

  30. Pniewski T, Kapusta J, Bociąg P, Wojciechowicz J, Kostrzak A, Gdula M, Fedorowicz-Strońska O, Wójcik P, Otta H, Samardakiewicz S, Wolko B, Płucienniczak A (2011) Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation. J Appl Genet 52:125–136

  31. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB et al (2014) Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53

  32. Rosales-Mendoza S, Salazar-González JA (2014) Immunological aspects of using plant cells as delivery vehicles for oral vaccines. Expert Rev Vaccines 13:737–749

  33. Salazar-Gonzalez JA, Rosales-Mendoza S, Romero-Maldonado A, Monreal-Escalante E, Uresti-Rivera EE, Bañuelos-Hernández B (2014) Production of a plant-derived immunogenic protein targeting ApoB100 and CETP: toward a plant-based atherosclerosis vaccine. Mol Biotechnol 56:1133–1142

  34. Sun Y, Carrion R Jr, Ye L, Wen Z, Ro YT, Brasky K, Ticer AE, Schwegler EE, Patterson JL, Compans RW, Yang C (2009) Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 383:12–21

  35. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S (2005) Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23:3033–3042

  36. Tacket CO (2009) Plant-based oral vaccines: results of human trials. Curr Topics Microbiol Immunol 332:103–117

  37. Takeyama N, Kiyono H, Yuki Y (2015) Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccines 3:139–154

  38. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S (2003) Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 100:15889–15894

  39. Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S (2005) Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 175:1184–1191

  40. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2:430–437

  41. WHO (2014) Ebola virus disease. http://www.who.int/mediacentre/factsheets/fs103/en Accessed 23 June 2016

  42. WHO (2015) Ebola situation report. http://apps.who.int/ebola/ebola-situation-reports Accessed 23 June 2016

Download references

Acknowledgements

Current investigations from the group are supported by CONACYT/México (Grants INFR-2016-271182 and CB-256063 to SRM; and Grants CB-2010-01, 151818 and INFR-2014-01, 225924 to CA).

Author information

Correspondence to Sergio Rosales-Mendoza.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 922 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Monreal-Escalante, E., Ramos-Vega, A.A., Salazar-González, J.A. et al. Expression of the VP40 antigen from the Zaire ebolavirus in tobacco plants. Planta 246, 123–132 (2017). https://doi.org/10.1007/s00425-017-2689-5

Download citation

Keywords

  • Antigen delivery system
  • Ebola
  • Humoral response
  • Molecular pharming
  • Oral vaccine
  • Subunit vaccine